医学
奥马佐单抗
哮喘
肺活量
恶化
生物仿制药
随机对照试验
临床试验
内科学
麻醉
免疫球蛋白E
肺
免疫学
抗体
肺功能
扩散能力
作者
Prasad Apsangikar,Pravin Ghadge,Manoj Naik,Santosh Nair
出处
期刊:PubMed
日期:2020-12-01
卷期号:68 (12): 61-65
被引量:10
摘要
The evaluation of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity was concluded to show no meaningful clinical difference of the biosimilar omalizumab with the reference product.
科研通智能强力驱动
Strongly Powered by AbleSci AI